SSTR2 and hepatocellular carcinoma: To address this gap, we examined the efficacy of approved SSTR2-targeted radiopharmaceuticals in HCC cell lines and animal models, aiming to assess its potential as a novel imaging and therapeutic modality for this malignancy.